@lilyswrobel's peptide therapy claims need context

What did @lilyswrobel actually say?

Lily described being in the "purging stage of GHK-Cu," saying her back has developed "so many new spots" and she's now getting them on her neck, an area she says was previously unaffected. She's framing new, painful, inflamed breakouts as a temporary detox-style phase caused by the peptide itself. That's a specific mechanism she's assigning to GHK-Cu, and it's worth pulling apart.

To be fair, she's not claiming a cure or a miracle. She sounds genuinely uncomfortable and committed to seeing it through. But the word "purging" carries a lot of implied biology that the evidence doesn't cleanly support here.

Does the science back this up?

Not really, at least not in the way she's framing it. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that has shown anti-inflammatory, antioxidant, and wound-healing properties in cell and animal studies. Pickart and Margolina (2018, Cosmetics) summarized decades of GHK-Cu research showing it stimulates collagen synthesis and modulates inflammatory signaling. None of that research describes a systemic "purge" response.

The "skin purging" concept has some legitimate grounding in dermatology, but it's specifically associated with topical retinoids and chemical exfoliants that accelerate cell turnover. Kligman (1969, JAMA) originally described this with tretinoin. GHK-Cu doesn't work through that same keratinocyte-acceleration mechanism, so applying the same purging logic is a stretch. New breakouts appearing in previously unaffected areas, like her neck, is actually a red flag in dermatology, not a reassuring sign of progress.

What did they get wrong (or right)?

Here's the honest breakdown. The claim that GHK-Cu promotes skin repair and healing has real research support. That part is fine. The leap to "this is a purge stage" is where the science gets shaky. There is no peer-reviewed clinical evidence documenting a GHK-Cu-induced purge response in humans using subcutaneous or topical application.

What she got genuinely wrong is the interpretation of new-site breakouts as a sign the peptide is working. Breakouts spreading to new anatomical areas, especially with inflammation and pain, should not be casually attributed to a peptide's detox mechanism. That pattern could reflect irritant folliculitis, injection site reactions, or an unrelated skin condition being exacerbated. Claiming a peptide is "purging" your system is also the kind of language that borrows credibility from legitimate dermatology and applies it somewhere it doesn't fit.

What should you actually know?

If you're using GHK-Cu and developing new, painful inflammatory lesions in areas that weren't previously affected, that's a signal worth discussing with a dermatologist or prescribing clinician, not just waiting out. The peptide does have a reasonable safety profile in the literature, but that doesn't mean every adverse skin response should be reframed as therapeutic progress.

The broader issue is that the "purging" narrative is pervasive in skincare and peptide communities online. It functions as a convenient explanation for worsening symptoms, which can delay people from seeking appropriate evaluation. Rigel et al. (2005, Journal of the American Academy of Dermatology) noted that delayed dermatological assessment for inflammatory skin conditions often results in worse long-term scarring outcomes. Lily herself mentions she already has significant scarring. Adding more inflamed lesions while waiting for a purge that may not be real is a risk worth naming plainly.

• GHK-Cu does not have a documented clinical mechanism that causes a skin purge.
• New-site breakouts are not a validated sign of peptide efficacy.
• If symptoms are spreading and painful, get a clinical opinion before continuing.